Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | MGAM | O43451 | 1/20 | 0.44 |
| ▸ | SI | P14410 | 1/20 | 0.44 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | GSK3A | P49840 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13550899 | 0.87 | ALDH1A1 (0.33) | ALDH1A1TSHRKMT2AMEN1 | |
| SCHEMBL4869552 | 0.83 | GAA (0.44) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL12715665 | 0.81 | GAA (0.46) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL14157029 | 0.80 | CYP1A2 (0.42) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL1466765 | 0.79 | GAA (0.44) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL13079905 | 0.78 | TSHR (0.40) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL15445438 | 0.78 | GAA (0.43) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL5503646 | 0.77 | CYP1A2 (0.48) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL14016347 | 0.76 | MEN1 (0.46) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL7936528 | 0.76 | KMT2A (0.42) | GAAMGAMSIMGAM2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260027131-A1 | PRODRUGS, PRODRUG COMPOSITIONS AND RELATED METHODS | PRAESIDIA BIOTHERAPEUTICS INC (US) | 2026-01-29 | — | — | US | disclosed |
| WO-2024020379-A2 | PRODRUGS, PRODRUG COMPOSITIONS AND RELATED METHODS | PRAESIDIA BIOTHERAPEUTICS INC. (US) | 2024-01-25 | — | — | WO | disclosed |
| WO-2024020379-A2 | PRODRUGS, PRODRUG COMPOSITIONS AND RELATED METHODS | PRAESIDIA BIOTHERAPEUTICS INC. (US) | 2024-01-25 | — | — | WO | disclosed |
| US-11661403-B2 | Oxadiazole compounds | VIVACE THERAPEUTICS, INC. (US) | 2023-05-30 | — | — | US | disclosed |
| US-11661403-B2 | Oxadiazole compounds | VIVACE THERAPEUTICS, INC. (US) | 2023-05-30 | — | — | US | disclosed |
| US-20210238154-A1 | OXADIAZOLE COMPOUNDS | VIVACE THERAPEUTICS, INC. | 2021-08-05 | — | — | US | disclosed |
| US-20210238154-A1 | OXADIAZOLE COMPOUNDS | VIVACE THERAPEUTICS, INC. | 2021-08-05 | — | — | US | disclosed |
| EP-3793551-A1 | OXADIAZOLE COMPOUNDS | Vivace Therapeutics, Inc. (US) | 2021-03-24 | — | — | EP | disclosed |
| WO-2019222431-A9 | OXADIAZOLE COMPOUNDS | VIVACE THERAPEUTICS, INC. (US) | 2020-10-22 | — | — | WO | disclosed |
| WO-2019222431-A9 | OXADIAZOLE COMPOUNDS | VIVACE THERAPEUTICS, INC. (US) | 2020-10-22 | — | — | WO | disclosed |
| US-20170107207-A1 | AMINOPYRAZOLONE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-04-20 | — | — | US | disclosed |
| US-20170107207-A1 | AMINOPYRAZOLONE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-04-20 | — | — | US | disclosed |
| US-20170107207-A1 | AMINOPYRAZOLONE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-04-20 | — | — | US | disclosed |
| EP-3109239-A1 | AMINOPYRAZOLONE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-12-28 | — | — | EP | disclosed |
| WO-2015125786-A1 | AMINOPYRAZOLONE DERIVATIVE | 第一三共株式会社 | 2015-08-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260027131-A1 | PRODRUGS, PRODRUG COMPOSITIONS AND RELATED METHODS | DNPEP, SLC7A1, SLC6A7 | GAA 2035/4885MGAM 3254/4885SI 404/4885 |
| US-20210238154-A1 | OXADIAZOLE COMPOUNDS | YAP1, TEAD2, TEAD3 | GAA 3514/4885MGAM 4707/4885SI 3919/4885 |
| US-11661403-B2 | Oxadiazole compounds | YAP1, TEAD2, TEAD3 | GAA 3514/4885MGAM 4707/4885SI 3919/4885 |
| US-20170107207-A1 | AMINOPYRAZOLONE DERIVATIVE | ATAD5, ATP1A1, TIPRL | GAA 2530/4885MGAM 4640/4885SI 4262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.